The launches of Vyzulta, Rhopressa, and preservative-free formulations promise to boost manufacturers’ revenues during the next 5 years in the global glaucoma pharmaceuticals market.
The upswing follows years of declining revenues as branded products lost patent protection and the market shifted to generics.
Market Scope forecasts the segment will grow from $4.8 billion in 2018 to $6.6 billion in 2023 at a compound annual growth rate of 6.6 percent.
The new classes of nitric oxide-donating compounds (Bausch + Lomb’s Vyzulta) and Rho-kinase (ROCK) inhibitors (Aerie’s Rhopressa) open up new possibilities for fixed combination drugs, which as a class were already gaining market share around the world.
An estimated 66 million people have primary open-angle glaucoma or exfoliation glaucoma, while another 18 million people have primary angle-closure glaucoma. More than 37 million people have ocular hypertension, a condition characterized by higher-than-normal intraocular pressure (IOP) without any identifiable glaucoma-associated damage. Ocular hypertension is the leading risk factor for glaucoma, and many people diagnosed with ocular hypertension take pressure-lowering glaucoma drugs to reduce the risk of developing glaucoma.
Nine classes of drugs, including NO-donating compounds, ROCK inhibitors, and fixed combination drugs, fill the medicine chest of pharmaceutical glaucoma treatments, but prostaglandin agonists treat the most patients, accounting for over half of prescriptions in the US and 28 percent of prescriptions worldwide.
Market Scope’s newly published 2018 Glaucoma Pharmaceuticals Report looks in depth at treatment options and opportunities for growth through 2023. The report includes expanded discussions of exfoliation syndrome and normal tension glaucoma, types of glaucoma that are important in some geographic areas, but not others, and a new review of genetic research that may lead to future treatments.
The report analyses 61 marketed medications and differences in their popularity around the world, 16 pipeline agents in development, 22 discontinued drug candidates, 10 clinical stage alternative drug delivery platforms, 10 preclinical alternative drug delivery platform programs, and another nine university-based drug delivery research programs.
Market Scope’s “2018 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2017 to 2023” was published in June.